Exploring QSAR for substituted 2-sulfonyl-phenyl-indol derivatives as potent and selective COX-2 inhibitors using different chemometrics tools

Chemical Biology and Drug Design

Volumn 72, Issue 6, 2008, Pages 564-574

  Khoshneviszadeh, Mehdi ^a   Edraki, Najmeh ^a   Miri, Ramin ^a   Hemmateenejad, Bahram ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY   (Iran)

Author keywords

2 sulfonyl phenyl indole; Chemometrics; COX 2 inhibitors; QSAR

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; BENZENE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOLE DERIVATIVE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROFECOXIB; SULFONE DERIVATIVE;

ALGORITHM; ARTICLE; CHEMOMETRICS; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FACTORIAL ANALYSIS; LIPOPHILICITY; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ALGORITHMS; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; INDOLES; LEAST-SQUARES ANALYSIS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; SOFTWARE;

EID: 56649107750     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00735.x     Document Type: Article

References (53)

1. Vane J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231 : 232 235.
2. Almansa C., Alfon J., deArriba A.F., Cavalcanti F.L., Escamilla I., Gomez L.A. (2003) Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. J Med Chem 46 : 3463 3475.
3. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Pro Natl Acad Sci 88 : 2692 2696.
4. Joo Y.H., Kim J.K., Kang S.H., Noh M.S., Ha J.Y., Choi J.K., Lim K.M., Lee C.H., Chung S. (2003) 2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13 : 413 417.
5. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower J.R., Vane J.R. (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 90 : 11693 11697.
6. Habeeb G., Praveen P.N., Knaus E.E. (2001) Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem 44 : 2921 2927.
7. Prescott S.M., White R.L. (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87 : 783 786.
8. Bosch J., Roca T., Catena J.L., Liorens O., Perez J.J., Lagunas C., Fernandez A.G., Miquel I., Fernandez-Serrat A., Farrerons C. (2000) Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 10 : 1745 1748.
9. Futaki N., Yashikawa K., Hamasaka Y., Arai I., Higuchi S., lizuka H., Otomo S. (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24 : 105 110.
10. Gans k., Galbraith W., Roman R.J., Haber S.B., Kerr J.S., Schmidt W.K., Smith C., Hewes W.E., Ackerman N.R. (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254 : 180 187.
11. Penning T., Talley J., Bertenshaw S., Carter J., Collins P., Docter S., Graneto M. et al. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40 : 1347 1365.
12. Kagutkar A.S., Marnett A.B., Crews B.C., Remmel R.P., Marnett L.J. (2000) Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43 : 2860 2870.
13. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.s., Seibert K. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43 : 775 777.
14. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P. et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296 : 558 566.
15. Talley J.J., Bertershaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Koboldt C.M., Yuan J., Zhang Y.Y., Seibert K. (2000) N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43 : 1661 1663.
16. Shahapurkar S., Pandya T., Kawathekar N., Chaturvedi S.C. (2004) Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors. Eur J Med Chem 39 : 899 904.
17. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A. (1999) Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 274 : 22903 22906.
18. Kiefer J.R., Pawlitz J.L., Moreland K.T., Stegeman R.A., Hood W.F., Gierse J.K., Stevens A.M., Goodwin D.C., Rowlinson S.W., Marnett L.J., Stallings W.C., Kurumbail R.G. (2000) Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 405 : 97 101.
19. Khanapure S.P., Garvey D.S., Young D.V., Ezawa M., Earl R.A., Gaston R.D., Fang X., Murty M., Martino A., Shumway M., Trocha M., Mark P., Janero D.R. (2003) Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J Med Chem 46 : 5484 5504.
20. Picot D., Loll P.J., Garavito R.M. (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367 : 243 249.
21. Dannhardt G., Laufer S. (2000) Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr Med Chem 7 : 1101 1112.
22. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromlish W., Ethier D. et al. (1999) The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9 : 1773 1778.
23. Reitz D.B., Li J.J., Norton M.B., Reinhard E.J., Collins J.T., Anderson G.D., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K. (1994) Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 37 : 3878 3881.
24. Black W.C., Brideau C., Chan C.C., Charleson S., Chauret N., Claveau D., Ethier D. et al. (1999) 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. J Med Chem 42 : 1274 4578.
25. Li J.J., Anderson G.D., Burton E.G., Cogburn J.N., Collins J.T., Garland D.J., Gregory S.A., Huang H.C., Isakson P.C., Koboldt C.M. (1995) 1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem 38 : 4570 4578.
26. Khanna I.K., Yu Y., Huff R.M., Weier R.M., Xu X., Koszyk F.J., Collins P.W. et al. (2000) Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. J Med Chem 43 : 3168 3185.
27. Khanna I.K., Weier R.M., Yu Y., Collins P.W., Miyashiro J.M., Koboldt C.M., Veenhuizen A.W., Currie J.L., Seibert K., Isakson P.C. (1997) 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem 40 : 1619 1633.
28. Matsushita M., Masaki M., Yagi Y., Tanaka T., Wakitani K. (1997) Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm Res 46 : 461 466.
29. Puig C., Crespo M.I., Godessart N., Feixas J., Ibarzo J., Jimenez J.M., Soca L. et al. (2000) Synthesis and biological evaluation of 3,4-diaryloxazolones: a new class of orally active cyclooxygenase-2 inhibitors. J Med Chem 43 : 214 223.
30. Huang H.C., Li J.J., Garland D.J., Chamberlain T.S., Reinhard E.J., Manning R.E., Seibert K. et al. (1996) Synthesis and biological evaluation of 3,4-diaryloxazolones: a new class of orally active cyclooxygenase-2 inhibitors. J Med Chem 39 : 253 266.
31. FÜrstner A., Hupperts A., Ptock A., Janssen E. (1994) 'Site selective' formation of low-valent titanium reagents: an 'instant' procedure for the reductive coupling of Oxo amides to indoles. J Org Chem 59 : 5215.
32. Hansch C., Hoekman D., Gao H. (1996) Comparative QSAR: toward a deeper understanding of chemicobiological interactions. Chem Rev 96 : 1045 1075.
33. Mohajeri A., Hemmateenejad B., Mehdipour A.R., Miri R. (2008) Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS. J Mol Graph Mod 26 : 1057 1065.
34. Hemmateenejad B., Miri R., Edraki N., Khoshneviszadeh M., Shafiee A. (2007) Molecular modeling and QSAR analysis of some 4,5-dichloroimidazolyl-1,4- DHP based calcium channel blockers. J Iran Chem Soc 4 : 182 193.
35. Edraki N., Hemmateenejad B., Miri R., Khoshneviszadeh M. (2007) QSAR study of phenoxypyrimidine derivatives as potent inhibitors of p38 kinase using different chemometric tools. Chem Biol Drug Des 70 : 530 539.
36. Reddy R.N., Mutyala R., Aparoy P., Reddanna P., Reddy M.R. (2007) Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. Curr Pharm Des 43 : 1559 1569.
37. Hu W., Guo Z., Chu F., Bai A., Yi X., Cheng G., Li J. (2003) Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors. J Bioorg Med Chem 11 : 1153 1160.
38. Safarpour M.A., Hemmateenejad B., Miri R., Jamali M. (2004) Quantum chemical-QSAR study of some newly synthesized 1,4-dihydropyridine calcium channel blockers. QSAR Comb Sci 22 : 997 1005.
39. Darlington R.B. (1990) Regression and Linear Models. New York : McGrawHill.
40. Leonard J.T., Roy K. (2006) QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques. Bioorg Med Chem 14 : 1039 1046.
41. Franke R. (1984) Theoretical Drug Design Methods. Amsterdam : Elsevier p. 184.
42. Franke R., Gruska A. (1995) Methods and Principles in Medicinal Chemistry. In : van Waterbeemd H., editor. Chemometric Methods in Molecular Design. Weinheim : VCH p. 113.
43. Kubinyi H. (1995) The Quantitative Analysis of Structure-Activity Relationships. In : Wolff M.E., editor. Burger's Medicinal Chemistry and Drug Discovery, 5th edn, Vol. I. New York : Wiley 507 pp.
44. Wold S. (1995) Chemometric Methods in Molecular Design. Weinheim : VCH.
45. Fan Y., Shi L.M., Kohn K.W., Pommier Y., Weinstein J.N. (2001) Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J Med Chem 44 : 3254 3263.
46. Bhattacharya P., Roy K. (2005) QSAR of adenosine A3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools. Bioorg Med Chem Lett 15 : 3737 3743.
47. Cho S.J., Hermsmeier M.A. (2002) Genetic algorithm guided selection: variable selection and subset selection. J Chem Inf Comput Sci 42 : 927 936.
48. Todeschini R., Consonni V., Mannhold R. (2000) Handbook of Molecular Descriptors. In : Kubinyi H., Timmerman H., editors. Methods and Principles in Medicinal Chemistry. Weinheim, Germany : Wiley- VCH.
49. Tropsha A., Gramatica P., Gombar V.K. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 22 : 69 77.
50. 2. J Mol Graph Model 20 : 269 276.
51. Roy P., Roy K. (2008) On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 27 : 302 313.
52. Hansch C., Bonavida B., Jazirehi A.R., Cohen J.J., Milliron C., Kurup A. (2003) Quantitative structure-activity relationships of phenolic compounds causing apoptosis. Bioorg Med Chem 11 : 617 620.
53. Gupta A.K., Gupta R.A., Soni L.K., Kaskhedikar S.G. (2008) Exploration of physicochemical properties and molecular modeling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors. Eur J Med Chem 43 : 1297 1303.